Clinical Trial Update: BCD-236 in Combination With Chemotherapy in Patients With Relapsed and/or Metastatic Triple Negative Breast Cancer [Phase 2]

View source ↗

Summary

Biocad's BCD-236 is being studied in combination with chemotherapy for relapsed and/or metastatic triple-negative breast cancer in a Phase 2 trial that is curre…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• BCD-236

Snippet

Sponsor: Biocad | Conditions: Triple Negative Breast Cancer | Phase 2 | Status: RECRUITING